Skip to main content
. 2023 May 25;112(12):1766–1777. doi: 10.1007/s00392-023-02222-3

Table 1.

Baseline characteristics

Variable Study population (n = 20)
Age (years), median [25th–75th percentiles] 66.2 [61.2–70.8]
Female sex, n (%) 11 (55)
Body Mass Index (kg/m2), mean ± SD 30.9 ± 5.6
Cardiovascular risk factors
 Hypertension, n (%) 20 (100)
 Diabetes, n (%) 2 (10)
 Dyslipidemia, n (%) 8 (40)
 Smoking
  Ever-smoking, n (%) 4 (20)
  Current smoking, n (%) 1 (5)
 Family history of ischemic heart disease, n (%) 4 (20)
Arrhythmia-related history
 Atrial fibrillation
  Paroxysmal atrial fibrillation, n (%) 18 (90)
  Persistent atrial fibrillation, n (%) 2 (10)
 Cardioversion
  Electrical cardioversion, n (%) 10 (50)
  Chemical cardioversion, n (%) 2 (10)
 Flutter ablation, n (%) 1 (5)
 Pulmonic vein isolation, n (%) 4 (20)
 MAZE procedure, n (%) 0 (0)
 Left Atrial Appendage Occluder, n (%) 2 (10)
Prescribed medication
 Antiarrhythmic drugs
  Defined daily dosages, median [25th–75th percentiles] 1.0 [0.5–1.3]
  Number of drugs, median [25th–75th percentiles] 1.0 [1.0–1.3]
 Antihypertensive drugs
  Defined daily dosages, mean ± SD 2.7 ± 1.6
  Number of drugs, median [25th–75th percentile] 2.0 [2.0–3.0]
Blood pressure
 Mean 24-h ambulatory BP (mmHg), mean ± SD 129.5/77.3 ± 15.5/9.3
 Daytime ambulatory BP (mmHg), mean ± SD 132.3/79.5 ± 15.8/9.7
 Nighttime ambulatory BP (mmHg), mean ± SD 120.7/70.1 ± 17.4/10.4
 Office BP (mmHg), mean ± SD 153.8/87.5 ± 15.2/10.4
Quality-of-life
 Overall AFEQT score (range 0–100), mean ± SD 66.4 ± 15.0

AFEQT Atrial Fibrillation Effect on QualiTy-of-Life, BP blood pressure, EHRA European Heart Rhythm Association, SD standard deviation